New AACR D3 data mark a significant milestone for functional precision medicine, arriving as ASCO formally affirms the field as the future of care
MADISON, Wis., July 24, 2026 /PRNewswire/ -- Elephas Biosciences Corporation, a private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced new data at the American Association for Cancer Research Drug Discovery and Development (AACR D3) conference. The data show that the elive platform, already shown to measure response to immune checkpoint inhibitors (ICIs), now can support targeted therapies as well.
Read more at prnewswire.com